Lost brain cell function, a precursor to schizophrenia and cognitive disability has been found restored, to a degree, in mice who have been given an anticancer drug that contains p21-activated kinase (PAK) inhibitors.
PAKs are expected to work for negative conditions in the brain like cancer, Fragile X Syndrome, Neurofibromatosis (both type 1 and 2), and a number of Autism Spectrum Disorders.
A study by Johns Hopkins Hospital finds promising potential for this experimental drug to be developed for use as a therapy for schizophrenia in humans.
The results of the experiment are not conclusive as there are not enough studies conducted so far, however behaviors in rodent-type schizophrenic symptoms have been reduced and normalized. The sample of mice used were those considered 'teenagers".
There is potential, also, for this drug to not only reverse but also block future incident of damage. Johns Hopkins representative Sawa says that this drug has that potential.